• Species Reactivity

  Human

• Specificity

  Detects human CD30/TNFRSF8 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse CD30, recombinant human (rh) CD27, and rhCD40 is observed.

• Source

  Monoclonal Mouse IgG2b Clone # 81337

• Immunogen

  S. frugiperda insect ovarian cell line     Sf 21-derived recombinant human CD30/TNFRSF8    
  Phe19-Lys379    
  Accession # P28908

• Formulation

  Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

• Label

  Alexa Fluor 488

Applications

• Recommended    
  Concentration

  Sample

• Flow Cytometry

  0.25-1 µg/10    ⁶ cells

  Jurkat human acute T cell leukemia cell line

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Shipping

  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

• Stability & Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: CD30/TNFRSF8

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 - 6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

• References:

1. Kennedy, M.K. et al. (2006) Immunology 118:143.

2. Tarkowski, M. (2003) Curr. Opin. Hematol. 10:267.

3. Durkop, H. et al. (1992) Cell 68:421.

4. Hamann, D. et al. (1996) J. Immunol. 156:1387.

5. Shanebeck, S.D. et al. (1995) Eur. J. Immunol. 25:2147.

6. Gruss, H.-J. et al. (1994) Blood 83:2045.

7. Oflzoglu E. et al. (2009) Adv. Exp. Med. Biol. 647:174.

8. Del Prete, G. et al. (1995) J. Exp. Med. 182:1655.

9. Harlin, H. et al. (2002) J. Immunol. 169:2451.

10. Amakawa, R. et al. (1996) Cell 84:551.

11. Chiarle, R. et al. (1999) J. Immunol. 163:194.

12. Vinante, F. et al. (2002) Blood 99:52.

13. Hansen, H.P. et al. (1995) Int. J. Cancer 63:750.

14. Hansen, H.P. et al. (2000) J. Immunol. 165:6703.

15. Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. 32:163.

• Entrez Gene IDs:

  943 (Human); 21941 (Mouse); 25069 (Rat)

• Alternate Names:

  CD30 antigen; CD30; CD30KI-1; CD30L receptor; cytokine receptor CD30; D1S166EKi-1; Ki-1 antigen; Lymphocyte activation antigen CD30; TNFRSF8; tumor necrosis factor receptor superfamily member 8; tumor necrosis factor receptor superfamily, member 8